Abstract: Disclosed are various methods for transmitting or receiving data or control information having high reliability conditions. A method for operating a terminal which transmits uplink control information (UCI) includes: a step of generating UCI; a step of comparing the priority of an uplink (UL) control channel for the transmission of the UCI with the priority of a UL data channel when some symbols of the UL control channel and the UL data channel overlap; and a step of selecting the UL channel having a higher priority among the UL control channel and the UL data channel, and transmitting the UCI to a base station through the selected UL channel.

Abstract: A mother substrate for a display panel and a display panel using the same are disclosed. A mother substrate for a display panel includes a conductive ring disposed in a non-display area outside the display area and surrounding each of the display areas, and one or more dummy pixel driving circuits disposed in a non-display area outside the display area. An electrostatic discharge (ESD) prevention structure inside the dummy pixel driving circuit can prevent defects of display panels due to ESD occurring in the manufacturing process of the display panel.

Abstract: A display apparatus according to an exemplary embodiment is disclosed. A display apparatus according to an exemplary embodiment includes a substrate having a bending region between an active area and a pad area. The display apparatus includes a planarization film on the active area and the pad area in the substrate. The display apparatus includes a first organic film coated on the planarization film, a second organic film coated on the first organic film, and a third organic film coated on the second organic film. The third organic film is formed such that an upper surface thereof is flattened in the active region. The display apparatus includes a plurality of light-emitting elements disposed on the third organic film.

Abstract: Provided are a substrate processing apparatus and a substrate processing method, which are capable of independently performing processes on a plurality of substrates in a multi-station chamber.

Abstract: Provided are stretchable electronics and a method for manufacturing the same. The stretchable electronics may include a substrate, a plurality of electronic elements disposed to be spaced apart from each other on the substrate, and a wire structure disposed on the substrate to connect the plurality of electronic elements to each other. The wire structure may include an insulator extending from one of the electronic elements to the other of the adjacent electronic elements and a metal wire configured to cover a top surface and side surfaces of the insulator. The insulator may include at least one bent part in a plan view.

Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: An embodiment discloses a display apparatus. The display apparatus includes a plurality of first electrodes and a contact electrode disposed on a substrate. The display apparatus includes a plurality of light-emitting elements disposed on the plurality of first electrodes. The display apparatus includes a first optical layer disposed between the plurality of light-emitting elements. The display apparatus includes a second electrode disposed on the plurality of light-emitting elements. The second electrode includes a first area disposed on the plurality of light-emitting elements and a second area extending outward from the first optical layer and electrically connected to the contact electrode. A plurality of signal wires connected to the plurality of first electrodes are provided, the second area of the second electrode comprises protruding portions extending to at least one of areas between the plurality of signal wires, and one of the protruding portions is connected to the contact electrode.

Abstract: A display device includes a plurality of first electrodes and a contact electrode on a substrate; a plurality of light-emitting elements on the plurality of first electrodes; a first optical layer between the plurality of light-emitting elements; and a second electrode on the plurality of light-emitting elements, the second electrode including a first region that is on the plurality of light-emitting elements and a second region that extends past an end the first optical layer and is in contact with the contact electrode.

Abstract: A mother substrate for a display panel and a display panel using the same are disclosed. The mother substrate comprises a plurality of display area including a plurality of light-emitting areas configured to receive light-emitting elements, a plurality of wirings, and a plurality of pads connected to the plurality of wirings; a conductive ring in a non-display area that surrounds the display area such that each of the display areas is surrounded by the conductive ring and electrically connected to the pads; a photoresist pattern covering the plurality of display areas and the non-display area; and a first metal layer covering the photoresist pattern. The conductive ring includes an electrostatic blocking area.

Abstract: A substrate treating apparatus in which foreign substances are reduced by using a foreign substance collecting unit includes a magnetic structure. The substrate treating apparatus includes a roller configured to be disposed on a rail extending in a first direction and attached to a side surface of a carrier unit to move along the rail, and a foreign substance collecting unit installed on the side surface of the carrier unit, moving together with the roller, and configured to be spaced apart from the rail when the roller is disposed on the rail, wherein the foreign substance collecting unit includes a magnetic structure for adsorbing foreign magnetic substances using a magnetic force, and a case surrounding the magnetic structure.

Abstract: The present disclosure relates to medical use of a compound of chemical formula 1 for treatment or prevention of pulmonary fibrosis. The present disclosure also relates to combination therapy with the compound of chemical formula 1 and nintedanib.

Abstract: The present invention provides: novel compounds capable of producing monomethyl fumarate after the compounds are administered; pharmaceutical compositions comprising same as active ingredients; and pharmaceutical uses thereof for treating or alleviating various diseases including immune system abnormalities, neurodegeneration, and/or inflammatory diseases.

Abstract: The present invention relates to a medical use of a compound, of Chemical Formula 1, for treating, alleviating or preventing non-alcoholic steatohepatitis (NASH) and/or hepatic fibrosis.

Abstract: The present invention relates to a pidolate salt and malate salt of a compound represented by a formula 1 with an excellent liquid-phase stability, solid-phase stability, water solubility, precipitation stability and hygroscopicity all together as a compound for preventing and treating diseases mediated by an acid pump antagonistic activity, as well as a method for preparing the same.

Abstract: The present invention relates to a pidolate salt and malate salt of a compound represented by a formula 1 with an excellent liquid-phase stability, solid-phase stability, water solubility, precipitation stability and hygroscopicity all together as a compound for preventing and treating diseases mediated by an acid pump antagonistic activity, as well as a method for preparing the same.

Abstract: The present disclosure provides a compound of a specific chemical structure or a pharmaceutically acceptable salt thereof, which has the activity of inhibiting and/or degrading mutant EGFR protein. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of cancer with EGFR mutation, especially lung cancer. The present disclosure also provides a method for treatment or prevention of EGFR mutation cancer, especially lung cancer, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing same to a subject in need of treatment.

Abstract: The present invention relates to a pidolate salt and malate salt of a compound represented by a formula 1 with an excellent liquid-phase stability, solid-phase stability, water solubility, precipitation stability and hygroscopicity all together as a compound for preventing and treating diseases mediated by an acid pump antagonistic activity, as well as a method for preparing the same.

Abstract: The present invention relates to a pidolate salt and malate salt of a compound represented by a formula 1 with an excellent liquid-phase stability, solid-phase stability, water solubility, precipitation stability and hygroscopicity all together as a compound for preventing and treating diseases mediated by an acid pump antagonistic activity, as well as a method for preparing the same.

Abstract: The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duchenne muscular atrophy, and a medicinal use of the novel compound.

Abstract: The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.